Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABBV AbbVie	$211.19 -0.4%	$190.48	$153.58 ▼ $218.66	$372.83B	0.61	6.15 million shs	5.56 million shs
AMGN Amgen	$312.64 +0.0%	$290.77	$253.30 ▼ $346.85	$167.95B	0.53	2.55 million shs	2.06 million shs
GILD Gilead Sciences	$113.35 -0.6%	$101.42	$62.07 ▼ $119.96	$141.96B	0.21	8.22 million shs	6.94 million shs
HARP Harpoon Therapeutics	$23.01	$22.89	$3.11 ▼ $23.21	$389.61M	2.11	1.52 million shs	N/A
MRNA Moderna	$34.30 -2.0%	$36.09	$29.25 ▼ $170.47	$13.23B	1.86	12.49 million shs	9.42 million shs
REGN Regeneron Pharmaceuticals	$680.61 -1.3%	$695.93	$642.00 ▼ $1,211.20	$74.41B	0.27	620,959 shs	863,695 shs
VRTX Vertex Pharmaceuticals	$502.92 +1.5%	$455.79	$377.85 ▼ $519.88	$129.14B	0.41	1.49 million shs	1.70 million shs

A Beginner's Guide to Investing in Cannabis

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABBV AbbVie	-0.29%	+0.23%	+10.10%	+21.82%	+17.40%
AMGN Amgen	+0.04%	-1.63%	+5.39%	+15.53%	+13.28%
GILD Gilead Sciences	-0.56%	-2.32%	+17.90%	+23.40%	+49.26%
HARP Harpoon Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
MRNA Moderna	-2.03%	0.00%	+10.90%	-18.00%	-67.80%
REGN Regeneron Pharmaceuticals	-1.29%	-2.55%	+2.28%	-6.93%	-29.50%
VRTX Vertex Pharmaceuticals	+1.51%	+3.54%	+10.48%	+8.45%	+21.71%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABBV AbbVie	4.6487 of 5 stars	2.4	5.0	3.3	3.9	3.0	2.5	1.3
AMGN Amgen	4.0309 of 5 stars	2.2	2.0	3.3	3.9	3.0	2.5	0.6
GILD Gilead Sciences	4.3815 of 5 stars	2.4	3.0	1.7	4.1	2.9	2.5	1.9
HARP Harpoon Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MRNA Moderna	4.1784 of 5 stars	4.0	1.0	0.0	4.6	2.1	2.5	0.6
REGN Regeneron Pharmaceuticals	4.6551 of 5 stars	4.4	3.0	1.7	2.3	2.0	1.7	1.9
VRTX Vertex Pharmaceuticals	3.8029 of 5 stars	2.3	3.0	0.0	3.3	2.9	2.5	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABBV AbbVie	2.88	Moderate Buy	$211.45	0.12% Upside
AMGN Amgen	2.46	Hold	$314.04	0.45% Upside
GILD Gilead Sciences	2.72	Moderate Buy	$104.52	-7.79% Downside
HARP Harpoon Therapeutics	3.00	Buy	N/A	N/A
MRNA Moderna	2.04	Hold	$59.60	73.76% Upside
REGN Regeneron Pharmaceuticals	2.76	Moderate Buy	$973.13	42.98% Upside
VRTX Vertex Pharmaceuticals	2.65	Moderate Buy	$506.70	0.75% Upside

Current Analyst Ratings Breakdown

Latest HARP, AMGN, GILD, REGN, VRTX, MRNA, and ABBV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/13/2025	MRNA Moderna	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$40.00
3/11/2025	GILD Gilead Sciences	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$123.00 ➝ $130.00
3/5/2025	AMGN Amgen	Johnson Rice Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$294.00
3/5/2025	ABBV AbbVie	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$210.00 ➝ $240.00
3/5/2025	AMGN Amgen	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Underperform ➝ Underperform	$275.00 ➝ $294.00
3/5/2025	GILD Gilead Sciences	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$116.00 ➝ $126.00
3/5/2025	GILD Gilead Sciences	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$120.00 ➝ $140.00
3/4/2025	ABBV AbbVie	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$200.00 ➝ $223.00
3/4/2025	GILD Gilead Sciences	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$115.00 ➝ $132.00
2/20/2025	VRTX Vertex Pharmaceuticals	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$407.00 ➝ $408.00
2/19/2025	MRNA Moderna	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$96.00 ➝ $78.00

(Data available from 3/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABBV AbbVie	$56.33B	6.62	$15.61 per share	13.53	$1.90 per share	111.15
AMGN Amgen	$33.42B	5.02	$31.33 per share	9.98	$10.93 per share	28.60
GILD Gilead Sciences	$28.75B	4.91	$8.95 per share	12.66	$15.44 per share	7.34
HARP Harpoon Therapeutics	$37.34M	10.43	N/A	N/A	$1.63 per share	14.12
MRNA Moderna	$3.20B	4.14	N/A	N/A	$28.33 per share	1.21
REGN Regeneron Pharmaceuticals	$14.20B	5.24	$44.69 per share	15.23	$268.50 per share	2.53
VRTX Vertex Pharmaceuticals	$11.02B	11.72	N/A	N/A	$63.90 per share	7.87

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABBV AbbVie	$4.28B	$2.40	88.00	15.11	1.62	7.59%	296.28%	12.65%	4/25/2025 (Estimated)
AMGN Amgen	$4.09B	$7.55	41.41	14.62	2.63	12.24%	176.32%	11.71%	5/1/2025 (Estimated)
GILD Gilead Sciences	$480M	$0.37	306.35	13.98	0.71	1.67%	31.63%	10.38%	4/24/2025 (Estimated)
HARP Harpoon Therapeutics	-$67.73M	-$8.76	N/A	N/A	N/A	-81.68%	-893.55%	-45.98%	N/A
MRNA Moderna	-$3.56B	-$9.28	N/A	N/A	N/A	-110.04%	-28.74%	-21.83%	5/1/2025 (Estimated)
REGN Regeneron Pharmaceuticals	$4.41B	$38.28	17.78	17.90	2.34	31.07%	16.32%	12.76%	5/1/2025 (Estimated)
VRTX Vertex Pharmaceuticals	-$535.60M	-$2.20	N/A	28.72	2.11	-4.86%	-2.02%	-1.49%	5/5/2025 (Estimated)

Latest HARP, AMGN, GILD, REGN, VRTX, MRNA, and ABBV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
2/11/2025	Q4 2024	GILD Gilead Sciences	$1.67	$1.90	+$0.23	$1.42	$7.15 billion	N/A
2/10/2025	Q4 2024	VRTX Vertex Pharmaceuticals	$3.99	$3.54	-$0.45	$3.50	$2.78 billion	N/A
2/4/2025	Q4 2024	AMGN Amgen	$5.04	$5.31	+$0.27	$1.16	$8.87 billion	N/A
2/4/2025	Q4 24	REGN Regeneron Pharmaceuticals	$11.21	$12.07	+$0.86	$8.06	$3.76 billion	$3.79 billion
1/31/2025	Q4 24	ABBV AbbVie	$2.98	$2.16	-$0.82	-$0.02	$14.81 billion	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABBV AbbVie	$6.56	3.11%	+6.04%	273.33%	53 Years
AMGN Amgen	$9.52	3.05%	+8.53%	126.09%	14 Years
GILD Gilead Sciences	$3.16	2.79%	+2.74%	854.05%	N/A
HARP Harpoon Therapeutics	N/A	N/A	N/A	N/A	N/A
MRNA Moderna	N/A	N/A	N/A	N/A	N/A
REGN Regeneron Pharmaceuticals	$0.88	0.13%	N/A	2.30%	N/A
VRTX Vertex Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Latest HARP, AMGN, GILD, REGN, VRTX, MRNA, and ABBV Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
3/4/2025	AMGN Amgen	quarterly	$2.38	3.05%	5/16/2025	5/16/2025	6/6/2025
2/14/2025	ABBV AbbVie	quarterly	$1.64	3.4%	4/15/2025	4/15/2025	5/15/2025
2/5/2025	GILD Gilead Sciences	quarterly	$0.79	3%	3/14/2025	3/14/2025	3/28/2025
2/20/2025	REGN Regeneron Pharmaceuticals	quarterly	$0.88	0.53%	2/20/2025	2/20/2025	3/20/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABBV AbbVie	17.94	0.66	0.55
AMGN Amgen	9.62	1.26	0.95
GILD Gilead Sciences	1.24	1.50	1.20
HARP Harpoon Therapeutics	N/A	1.89	1.89
MRNA Moderna	N/A	3.67	3.62
REGN Regeneron Pharmaceuticals	0.09	4.73	3.95
VRTX Vertex Pharmaceuticals	0.01	2.69	2.35

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABBV AbbVie	70.23%
AMGN Amgen	76.50%
GILD Gilead Sciences	83.67%
HARP Harpoon Therapeutics	74.01%
MRNA Moderna	75.33%
REGN Regeneron Pharmaceuticals	83.31%
VRTX Vertex Pharmaceuticals	90.96%

Insider Ownership

Company	Insider Ownership
ABBV AbbVie	0.25%
AMGN Amgen	0.69%
GILD Gilead Sciences	0.16%
HARP Harpoon Therapeutics	17.00%
MRNA Moderna	15.70%
REGN Regeneron Pharmaceuticals	7.48%
VRTX Vertex Pharmaceuticals	0.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABBV AbbVie	55,000	1.77 billion	1.76 billion	Optionable
AMGN Amgen	28,000	537.21 million	533.50 million	Optionable
GILD Gilead Sciences	18,000	1.25 billion	1.24 billion	Optionable
HARP Harpoon Therapeutics	53	16.93 million	14.05 million	Optionable
MRNA Moderna	5,600	385.82 million	324.40 million	Optionable
REGN Regeneron Pharmaceuticals	11,900	109.33 million	101.15 million	Optionable
VRTX Vertex Pharmaceuticals	6,100	256.79 million	256.28 million	Optionable

HARP, AMGN, GILD, REGN, VRTX, MRNA, and ABBV Headlines

Recent News About These Companies

Bowen Hanes & Co. Inc. Increases Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

March 14 at 6:18 AM | marketbeat.com

Skandinaviska Enskilda Banken AB publ Sells 14,251 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

March 14 at 6:17 AM | marketbeat.com

Erste Asset Management GmbH Buys 2,260 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

March 14 at 5:58 AM | marketbeat.com

3 No-Brainer Healthcare Stocks to Buy With $1,000 Right Now

March 14 at 5:51 AM | fool.com

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Acquired by Sequoia Financial Advisors LLC

March 14 at 4:36 AM | marketbeat.com

Why the Market Dipped But Vertex Pharmaceuticals (VRTX) Gained Today

March 13 at 6:55 PM | zacks.com

David Altshuler Sells 3,231 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Stock

March 13 at 4:23 PM | marketbeat.com

GILD vs. VRTX: Which Stock Is the Better Value Option?

March 13 at 1:09 PM | zacks.com

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by Jupiter Asset Management Ltd.

March 13 at 7:41 AM | marketbeat.com

Insider Selling: Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) EVP Sells 3,231 Shares of Stock

March 13 at 6:56 AM | insidertrades.com

Tredje AP fonden Has $55.35 Million Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

March 13 at 5:49 AM | marketbeat.com

Vestcor Inc Sells 12,624 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

March 13 at 5:48 AM | marketbeat.com

Swiss National Bank Cuts Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

March 13 at 5:39 AM | marketbeat.com

630 Shares in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Purchased by Natural Investments LLC

March 13 at 4:35 AM | marketbeat.com

Vertex Pharmaceuticals (NASDAQ:VRTX) Upgraded at StockNews.com

March 12 at 11:14 PM | marketbeat.com

Vertex Pharmaceuticals (VRTX) Outperforms Broader Market: What You Need to Know

March 12 at 8:42 PM | msn.com

Why Is Vertex (VRTX) Up 7.3% Since Last Earnings Report?

March 12 at 3:40 PM | msn.com

Why Vertex Pharmaceuticals Incorporated (VRTX) is the Best Pharma Stock to Buy According to Hedge Funds

March 12 at 2:57 PM | insidermonkey.com

Should You Consider Adding Vertex Pharmaceuticals Incorporated (VRTX) to Your Portfolio?

March 12 at 9:35 AM | insidermonkey.com

15,528 Shares in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Bought by Wealth High Governance Capital Ltda

March 12 at 6:22 AM | marketbeat.com

Wealthfront Advisers LLC Buys 32,997 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

March 12 at 5:43 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Gilead Sciences: 4 Reasons This Stock Has Much More To Rise
By Jea Yu | February 22, 2025
View Gilead Sciences: 4 Reasons This Stock Has Much More To Rise
Moderna: 4 Key Reasons the CEO Just Bought $5M in Shares
By Jea Yu | March 11, 2025
View Moderna: 4 Key Reasons the CEO Just Bought $5M in Shares
Moderna: A Generational Opportunity for Investors in 2025
By Thomas Hughes | February 19, 2025
View Moderna: A Generational Opportunity for Investors in 2025
High-Flying Defense Stocks Tumble: Market Jitters or DoD Cuts?
By Ryan Hasson | March 3, 2025
View High-Flying Defense Stocks Tumble: Market Jitters or DoD Cuts?
Not Just China: 3 European Stocks Gaining Investor Interest
By Sarah Horvath | February 28, 2025
View Not Just China: 3 European Stocks Gaining Investor Interest

HARP, AMGN, GILD, REGN, VRTX, MRNA, and ABBV Company Descriptions

AbbVie NYSE:ABBV

$211.19 -0.87 (-0.41%)

Closing price 03/13/2025 03:59 PM Eastern

Extended Trading

$212.58 +1.38 (+0.65%)

As of 03/13/2025 07:51 PM Eastern

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Amgen NASDAQ:AMGN

$312.64 +0.14 (+0.04%)

Closing price 03/13/2025 04:00 PM Eastern

Extended Trading

$312.48 -0.16 (-0.05%)

As of 03/13/2025 07:20 PM Eastern

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Gilead Sciences NASDAQ:GILD

$113.35 -0.64 (-0.56%)

Closing price 03/13/2025 04:00 PM Eastern

Extended Trading

$113.58 +0.23 (+0.20%)

As of 03/13/2025 07:57 PM Eastern

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Harpoon Therapeutics NASDAQ:HARP

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; and HPN217 that is in Phase I clinical trials for the treatment of multiple myeloma. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. It has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. The company was incorporated in 2015 and is headquartered in South San Francisco, California. As of March 11, 2024, Harpoon Therapeutics, Inc. operates as a subsidiary of Merck Sharp & Dohme LLC.

Moderna NASDAQ:MRNA

$34.30 -0.71 (-2.03%)

Closing price 03/13/2025 04:00 PM Eastern

Extended Trading

$34.55 +0.25 (+0.73%)

As of 03/13/2025 07:59 PM Eastern

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Regeneron Pharmaceuticals NASDAQ:REGN

$680.61 -8.89 (-1.29%)

Closing price 03/13/2025 04:00 PM Eastern

Extended Trading

$684.35 +3.74 (+0.55%)

As of 03/13/2025 07:55 PM Eastern

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Vertex Pharmaceuticals NASDAQ:VRTX

$502.92 +7.50 (+1.51%)

Closing price 03/13/2025 04:00 PM Eastern

Extended Trading

$506.42 +3.50 (+0.70%)

As of 03/13/2025 07:56 PM Eastern

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare MarketRank™

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest HARP, AMGN, GILD, REGN, VRTX, MRNA, and ABBV Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest HARP, AMGN, GILD, REGN, VRTX, MRNA, and ABBV Earnings

Compare Dividends

Latest HARP, AMGN, GILD, REGN, VRTX, MRNA, and ABBV Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

HARP, AMGN, GILD, REGN, VRTX, MRNA, and ABBV Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

HARP, AMGN, GILD, REGN, VRTX, MRNA, and ABBV Company Descriptions

AbbVie NYSE:ABBV

Amgen NASDAQ:AMGN

Gilead Sciences NASDAQ:GILD

Harpoon Therapeutics NASDAQ:HARP

Moderna NASDAQ:MRNA

Regeneron Pharmaceuticals NASDAQ:REGN

Vertex Pharmaceuticals NASDAQ:VRTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools